Each year, during the first full week of October, organizations across the country work to raise awareness for mental health disorders to educate the public, fight stigma and provide support. Mental health awareness is an important topic to address year-round, but Mental Illness Awareness Week is an opportunity to highlight the important work being done to improve the lives of Americans affected by mental health disorders.
Due to the U.S. Food and Drug Administration’s (FDA) comprehensive drug approval process, medicines on the U.S. market are widely regarded as the safest in the world. The U.S.’s relatively closed distribution system plays a critical role in helping to keep the global proliferation of counterfeit medicines from infiltrating the U.S. prescription medicine system.
We’ve talked before about Medicare Part D’s Extra Help program – also known as Low-Income Subsidies (LIS)—a program designed to help Medicare beneficiaries with limited incomes afford needed medicines.
Learn more about Part D Extra Help in our new video:
340B Spotlight: The latest 340B Spotlight explores contract pharmacy arrangements. Learn more about the history of contract pharmacy arrangements and why a policy change in 2010 led to a dramatic increase in the volume of contract pharmacies.
ICYMI: Dr. Murray Stewart, Chief Medical Officer of GSK, explains why clinical data transparency is the right thing to do and how it can benefit patients. Check it out here.
We’ve been covering 340B a lot in recent weeks, including areas of needed reform: how discounts work, levels of charity care among 340B hospitals and the relatively high rate of 340B hospitals acquiring physician practices.
Another aspect of 340B that deserves a closer look is contract pharmacy arrangements. But what are contract pharmacies and how do they work?
Contract pharmacy arrangements enable covered entities to contract with multiple independent retail pharmacies to dispense drugs receiving 340B discounts. The original purpose of these arrangements was to help small clinics who did not have their own in-house pharmacy. But a policy change in 2010 allowed all 340B entities – including large non-profit hospitals – to have an unlimited number of contract pharmacies. This change dramatically increased the number of contract pharmacies, but did nothing to ensure that patients either receive or benefit from the 340B discount.
By Dr. Murray Stewart, Chief Medical Officer, GSK
At times, there can be a huge gulf between principle and practice. For example, eating healthy foods and getting lots of exercise are clearly beneficial, but they require commitment and hard work and are not sustained by many people.
Expanding access to clinical trial information is another principle that attracts widespread support, but in practice, it takes a lot of commitment and hard work by many across the health care network. Despite the challenges, there have been significant strides made by the biopharmaceutical industry in putting this principle into practice.
Researchers can now access detailed trial data from many companies to support their own research and, hopefully, benefit medical science and patients. GSK and 11 other companies provide access to data through a common online website (www.clinicalstudydatarequest.com). Other companies have created their own systems consistent with the PhRMA-EFPIA Principles for Responsible Clinical Trial Data Sharing.
When Hurricane Katrina hit, the lack of communication between public health officials and the private sector, which controls most of the biopharmaceutical supply chain system slowed. This gap hindered efforts to deliver medications to patients in need. From the disaster, which marked its ten year anniversary in August, PhRMA, BIO, partners in the biopharmaceutical industry and the non-profit sector spearheaded the creation of Rx Response to streamline communication and tackle medicine delivery problems without delay or unnecessary phone chains.
Today, we celebrate more heartbeats with World Heart Day.
With a focus on cardiovascular disease and the promoting of healthier heart hygiene, World Heart Day is an opportunity to acknowledge advances in cardiovascular science and disease prevention. Even with heart disease topping the list of deadly diseases that affect patients in America today, death rates from heart disease and stroke are falling each year. This is thanks in large part to America’s biopharmaceutical research companies and their commitment to developing new treatments and cures.
We’ve written previously about Medicare Part B and what it covers, but today we are taking a closer look at how Medicare Part B pays for medicines. With some exceptions for certain classes, the current reimbursement methodology for Part B drugs administered in physician offices and hospital outpatient departments is Average Sales Price (ASP)+6 percent.
ASP is a market-based price that reflects the weighted average of all manufacturer sales prices and includes all rebates and discounts that are privately negotiated between manufacturers and purchasers (with the exception of Medicaid and certain federal discounts and rebates). This methodology mirrors reimbursement for physician-administered drugs in the commercial market.
Protecting Innovation: The current marketplace for prescription medicines helps keep spending in check and continued innovation for patients possible. A recent proposal by Presidential Candidate and former Secretary of State Hillary Clinton to regulate drug prices would have a myriad of consequences, including restricted access to medicines for patients, fewer innovative treatments, loss of the nation’s standing as a biomedical world leader and loss of countless jobs. Read more about the implications of the proposal here.
Americans Believe Medicines are Critical to Patient Health: A new poll from PhRMA and Morning Consult revealed that the majority of voters oppose allowing the federal government to set the price of prescription medicines and the vast majority of Americans believe prescription medicines help patients live longer, healthier lives. Find out more here.
Eliminating Hep C Could Reduce Future Spending: Take a look at Milliman’s new report that shows how eliminating hepatitis C today could reduce future U.S. health care spending by $115 billion over the next decade.